![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SIGLEC10 |
Gene summary for SIGLEC10 |
![]() |
Gene information | Species | Human | Gene symbol | SIGLEC10 | Gene ID | 89790 |
Gene name | sialic acid binding Ig like lectin 10 | |
Gene Alias | PRO940 | |
Cytomap | 19q13.41 | |
Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | B7ZL06 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
89790 | SIGLEC10 | HCC1 | Human | Liver | HCC | 3.16e-16 | 1.72e+00 | 0.5336 |
89790 | SIGLEC10 | HCC2 | Human | Liver | HCC | 1.00e-24 | 1.90e+00 | 0.5341 |
89790 | SIGLEC10 | HCC5 | Human | Liver | HCC | 2.49e-20 | 1.31e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190303421 | Liver | HCC | regulation of response to wounding | 94/7958 | 167/18723 | 2.19e-04 | 1.66e-03 | 94 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SIGLEC10 | SNV | Missense_Mutation | novel | c.575C>T | p.Pro192Leu | p.P192L | Q96LC7 | protein_coding | tolerated(0.16) | benign(0.3) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SIGLEC10 | SNV | Missense_Mutation | novel | c.1233N>T | p.Glu411Asp | p.E411D | Q96LC7 | protein_coding | deleterious(0.05) | possibly_damaging(0.692) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SIGLEC10 | SNV | Missense_Mutation | novel | c.964N>C | p.Thr322Pro | p.T322P | Q96LC7 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SIGLEC10 | SNV | Missense_Mutation | novel | c.773N>G | p.Gln258Arg | p.Q258R | Q96LC7 | protein_coding | tolerated(0.19) | benign(0.021) | TCGA-LL-A8F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SIGLEC10 | insertion | Frame_Shift_Ins | novel | c.2014_2015insCAGGAGTTCGAGACCAGTCTGAGCAACAGAGCGA | p.Phe672SerfsTer20 | p.F672Sfs*20 | Q96LC7 | protein_coding | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
SIGLEC10 | insertion | Nonsense_Mutation | novel | c.1876_1877insAAGAAATAACCATAAAAGTGGGCAACCAGCAGCTCTAGGCGCTGCTCT | p.Pro626delinsGlnGluIleThrIleLysValGlyAsnGlnGlnLeuTerAlaLeuLeuSer | p.P626delinsQEITIKVGNQQL*ALLS | Q96LC7 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
SIGLEC10 | SNV | Missense_Mutation | c.1987N>C | p.Glu663Gln | p.E663Q | Q96LC7 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
SIGLEC10 | SNV | Missense_Mutation | c.1525C>A | p.Leu509Ile | p.L509I | Q96LC7 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | SD | ||
SIGLEC10 | SNV | Missense_Mutation | rs575610342 | c.1751C>T | p.Pro584Leu | p.P584L | Q96LC7 | protein_coding | tolerated(0.54) | benign(0.003) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SIGLEC10 | SNV | Missense_Mutation | c.593N>T | p.Ser198Leu | p.S198L | Q96LC7 | protein_coding | deleterious(0.03) | possibly_damaging(0.905) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |